MeningitecMeningitec

Teresa Davis 2011

MeningitecMeningitec

Meningococcal Serogroup C Conjugate Meningococcal Serogroup C Conjugate VaccineVaccine

1 of 3 vaccines to protect against 1 of 3 vaccines to protect against Neisseria meningitidis group CNeisseria meningitidis group C

Does not proctect against A B W YDoes not proctect against A B W Y

Active IngredientsActive Ingredients

Each .5 ml dose contains 10ug of Neisseria Each .5 ml dose contains 10ug of Neisseria meningitidis Serogroup C oligosaccharide meningitidis Serogroup C oligosaccharide conjugated to 15ug Diphtheriae carrier protein.conjugated to 15ug Diphtheriae carrier protein.

Aluminium phosphateAluminium phosphate

Sodium chlorideSodium chloride

H2OH2O

PresentationPresentation

Prefilled syringe – without a needlePrefilled syringe – without a needle

.5 ml.5 ml

White suspensionWhite suspension

IndicationsIndications

For active immunisation from 6 weeks of For active immunisation from 6 weeks of age to prevent Neisseria meningitidis age to prevent Neisseria meningitidis serogroup Cserogroup C

Not recommended in any elderly Not recommended in any elderly populationspopulations

ContradicationsContradications

Hypersensitivity of any components of the Hypersensitivity of any components of the vaccine vaccine

Any significant neurological s&s or allergic or Any significant neurological s&s or allergic or anaphylactic reaction to prior dose of Meningitecanaphylactic reaction to prior dose of Meningitec

Severe febrile illnessSevere febrile illness

Does not contain eggs or nutsDoes not contain eggs or nuts

PrecautionsPrecautions

Coagulation disorders – Coagulation disorders – only because of the IM only because of the IM injectioninjection

Impaired immune responsive patients –Impaired immune responsive patients – may may have a reduce antibody response to active immunisationhave a reduce antibody response to active immunisation

Not recommended for pregnant or Not recommended for pregnant or

lactating motherslactating mothers

InteractionsInteractions

Can be administered at the same time as Can be administered at the same time as -Oral Polio, Hep B, Hib, DTaP and DT whole cell -Oral Polio, Hep B, Hib, DTaP and DT whole cell

Pertussis, PCV7 and MMRPertussis, PCV7 and MMR

Lower levels of Meningococcal C antibodies Lower levels of Meningococcal C antibodies have been reported with co-administration of have been reported with co-administration of Meningitec and aPMeningitec and aP

Spacing either simultaneously or at any time Spacing either simultaneously or at any time before or afterbefore or after

StorageStorage

Keep in original packagingKeep in original packaging

Refrigerate between 2 and 8 degrees CelsiusRefrigerate between 2 and 8 degrees Celsius

If exposed to temps above 8 degrees Celsius for If exposed to temps above 8 degrees Celsius for 48 hrs accumulatively – must be destroyed.48 hrs accumulatively – must be destroyed.

DO NOT freezeDO NOT freeze

AdministrationAdministration

Shake well before useShake well before use

IM injection onlyIM injection only

Anterolateral thigh in infants and deltoid in Anterolateral thigh in infants and deltoid in older children, adolescents and adultsolder children, adolescents and adults

NOT the gluteal areaNOT the gluteal area

Common (Mild) Adverse ReactionsCommon (Mild) Adverse Reactions

Local reactionLocal reaction Headache, dizziness and light-headednessHeadache, dizziness and light-headedness Aching musclesAching muscles Sleepiness or unsettled sleepSleepiness or unsettled sleep Feeling unwellFeeling unwell Unusual high- pitched cryUnusual high- pitched cry Reduced eating and drinkingReduced eating and drinking D’s and V’sD’s and V’s Stomach cramps or painStomach cramps or pain DyspepsiaDyspepsia FeverFever

Very Rare Adverse EventsVery Rare Adverse Events

Swollen glands in neck, armpits or groin Swollen glands in neck, armpits or groin HHE – hyptonic, hyporesponsive episodeHHE – hyptonic, hyporesponsive episode Pins and needlesPins and needles Petechiae or purpura Petechiae or purpura Loss of muscle toneLoss of muscle tone Decreased sensitivity to touch.Decreased sensitivity to touch.

OrderingOrdering

FAX TO:

Whangarei 09-438-9681

Northland District Health Board (NDHB) Meningitec Vaccine Fax Order Form

Account Name:Account No:

Delivery Address:

Date Required:

Contact Name: Contact Phone:

Special Delivery Instructions:

Vaccine DescriptionProprietary name

(manufacturer) of currently supplied vaccine

No of doses per pfs

Minimum quantity to

orderPRP

CODENo of doses

required

Meningococcal Serogroup C Conjugate Vaccine

.5ml Meningitec (Pfizer) 1 ? 1112045

Please note: If ordering in large volumes, it is recommended that you order the Meningitec vaccine in multiples of 70 doses as this will be the optimum quantity per chilly bin.

Authorised VaccinatorAuthorised Vaccinator

Standing OrdersStanding Orders

PerscriptionPerscription

APPLICATION FOR AUTHORISATION OF CURRENTLY AUTHORISED VACCINATORS

FOR THE MENINGOCOCCAL C VACCINATION PROGRAMME

VACCINATOR’S NAME: ……………………………………………..……………..………WORK POSTAL ADDRESS: ……………………………………………………………….

WORK PHONE NUMBER: …………………………………………………………………

Meningococcal C Immunisation Programme approved by the Medical Officer of Health , Northland District Health Board.

Please provide the following:

A copy of your current non-medical vaccinator authorisation

Please note that vaccinators intending to vaccinate in community-based settings (outreach or offsite) will also need to attach a copy of their Northland DHB Clinical Audit for Community-based Vaccinators.

1.A copy of your current practicing certificate.

Evidence of indemnity insurance

□ I have read the Meningitec® data sheet OR attended a Meningococcal C programme CNE session.Name: …………………………………………………………………………Signed: …………………………………………………………………………Date: ……/……/11

Out of the Programme DosageOut of the Programme Dosage

For infants less than 12 monthsFor infants less than 12 months

- three doses at least 1 month apart- three doses at least 1 month apart

- with a booster dose at or after 12 - with a booster dose at or after 12

monthsmonths

Very pre term babies – Very pre term babies – risk of apnoea – give and risk of apnoea – give and monitormonitor

ReferencesReferences

Consumer and Health Professional data Consumer and Health Professional data sheetssheets

Immunisation Handbook 2011 Immunisation Handbook 2011

Med Division Pfizer AustraliaMed Division Pfizer Australia

MeaslesMeasles

Monday 3 OctMonday 3 Oct

200 confirmed cases of measles in the Auckland 200 confirmed cases of measles in the Auckland region since 30 Mayregion since 30 May

0900 hour 10 confirmed cases reported between 0900 hour 10 confirmed cases reported between Friday 9 am and Monday 9 amFriday 9 am and Monday 9 am

a further 8 suspected cases under investigationa further 8 suspected cases under investigation